Molecular Weight: 256.73
Molecular Formula: C12H17N2O2Cl
Canonical SMILES: C1CN(CCN1)C2=C3C(=CC=C2)OCCO3.Cl
InChI: InChI=1S/C12H16N2O2.ClH/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12;/h1-3,13H,4-9H2;1H
InChIKey: JFSOSUNPIXJCIX-UHFFFAOYSA-N
Melting Point: 256-258 °C
Purity: >98 %
Solubility: DMSO: ≥ 31 mg/mL, H2O: ≥ 28 mg/mL
Application: Eltoprazine hydrochloride has been shown to reduce L-DOPA-induced dyskinesias in experimental models of Parkinson's Disease and in human patients. It is used as a novel drug for the treatment of anxiety as well as other neurological and mental disorders.
Storage: -20°C Freezer
Synonyms: Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-, monohydrochloride;1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine hydrochloride;DU-28853 hydrochloride;DU28853 hydrochloride
DescriptionEltoprazine hydrochloride is the hydrochloride form of Eltoprazine which is a serenic or antiaggressive agent. It acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor with Ki values of 40, 52 and 81 nM for 5-HT1A, 5-HT1B and 5-HT2C receptors respectively. It has been shown to reduce L-DOPA-induced dyskinesias in experimental models of Parkinson's Disease and in human patients, although this effect was accompanied by a partial worsening of the therapeutic effect of l-dopa in vivo. It is used as a novel drug for the treatment of anxiety as well as other neurological and mental disorders. It was developed by PsychoGenics and Amarantus Bioscience, Inc.. It is in clinical stage 3.
More details are to be found on
supplier website
